Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
clinical trials
life sciences
national blog main
5
×
amgen
eli lilly
fda
new york blog main
boston blog main
boston top stories
calcitonin gene-related peptide
indiana blog main
indiana top stories
migraine
national
national top stories
teva pharmaceutical
allergan
biohaven
boulder/denver blog main
boulder/denver top stories
chronic migraine
detroit blog main
detroit top stories
drugs
episodic migraine
eptinezumab
erenumab
fremanezumab
galcanezumab
migraine research foundation
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
What
class
5
×
new
5
×
fda
medicines
migraine
approval
drug
won
approved
developed
nod
pain
starts
adults
allergan
amgen
announced
arguments
based
begin
big
biosciences
bio’s
brings
bubbles
candidates
cells
clinical
codiak
commercialized
companies
competitors
decades
decision
drugs
eli
exosome
exosomes
formed
fund
Language
unset
Current search:
class
×
new
×
" national blog main "
×
@xconomy.com
3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines